TAS2R38 taster variants-linked MGAM expression in Alzheimer’s disease: a novel target for precision drug repurposing
This study is the first to report a genetic association between TAS2R38 and AD biomarkers. Our findings, validated in multiple cohorts/matching groups, suggest MGAM as a novel AD drug target with existing FDA-approved inhibitors and demonstrate the potential of TAS2R38 haplotypes to inform precision drug repurposing strategies for AD, which warrants further in-depth preclinical and clinical studies.
Authors
- EM Reiman
- Q. Wang
- Claire W. Su
- Teresa Wu
Institutions
- Alzheimer's Association (US)
- Banner Alzheimer’s Institute
- Arizona State University (US)
Publication Details
- Journal
- Frontiers in Aging Neuroscience
- Published
- 2026-03-04
- DOI
- https://doi.org/10.3389/fnagi.2026.1768436
- Primary Topic
- Biochemical Analysis and Sensing Techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Mayo Clinic
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Mayo Foundation for Medical Education and Research
- Meso Scale Diagnostics
- Arizona Department of Health Services
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- CurePSP
- Rush University
- Northern California Institute for Research and Education
- Translational Genomics Research Institute
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- Arizona Biomedical Research Commission
- National Institutes of Health
- Genentech
- University of California, San Diego
- Canadian Institutes of Health Research
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke